Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Unknown 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Myeloid 2Lymphoid 1

Conditions

Myelodysplastic Syndromes 6Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Multiple Myeloma 5Lymphoma, Non-Hodgkin 5Lymphoma 5Leukemia 5Myeloproliferative Disorders 4Hodgkin Disease 4Blast Crisis 4Myelodysplastic-Myeloproliferative Diseases 3Leukemia, Myelomonocytic, Chronic 3Leukemia, Myeloid, Chronic-Phase 3Leukemia, Myeloid, Acute 3Leukemia, Myeloid, Accelerated Phase 3Leukemia, Myelogenous, Chronic, BCR-ABL Positive 3Leukemia, Lymphocytic, Chronic, B-Cell 3Prostatic Neoplasms 2Primary Myelofibrosis 2Neoplasms, Plasma Cell 2Neoplasm Metastasis 2Lymphoma, Mantle-Cell 2Lymphoma, Large-Cell, Immunoblastic 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma, Follicular 2Lymphoma, B-Cell, Marginal Zone 2Lymphohistiocytosis, Hemophagocytic 2Leukemia, Prolymphocytic 2Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 2Leukemia, Biphenotypic, Acute 2Congenital Abnormalities 2

Interventions

Etoposide 7pegaspargase 5Methylprednisolone 4Dexamethasone 4Cyclophosphamide 3Alemtuzumab 3Gemcitabine 2Flow Cytometry 2Emapalumab 2Doxorubicin 2zanubrutinib 1tocilizumab 1sintilimab 1ruxolitinib 1fludarabine phosphate 1fludarabine 1Whole-Body Irradiation 1Vincristine 1Thiotepa 1Th1-Th2 Balance 1Tacrolimus 1Rituximab 1Prednisone 1Polymerase Chain Reaction 1N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 1Methylprednisolone Hemisuccinate 1Methotrexate 1Melphalan 1In Situ Hybridization 1Immunohistochemistry 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Lymphohistiocytosis, Hemophagocytic × Doxorubicin × Myeloid × Clear all
NCT01818908 2019-02-15

Trial of DA-EPOCH Regimen for NHL With HLH

The First Affiliated Hospital with Nanjing Medical University

Phase 2 Unknown
50 enrolled
LymphoidMyeloid

Lymphoma, Non-Hodgkin, Lymphohistiocytosis, Hemophagocytic

NCT02631109 2016-08-04

L-DEP Regimen as a Salvage Therapy for Refractory Epstein Barr Virus-induced Hemophagocytic Lymphohistiocytosis

Beijing Friendship Hospital

Phase 3 Unknown
120 enrolled
Myeloid

Epstein-Barr Virus Infections, Lymphohistiocytosis, Hemophagocytic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡